Section I
1341 – 1350 of 4729
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1)
(
- Contribution to journal › Article
-
Mark
Prognostic and Predictive Markers in Primary Breast Cancer - Quality Assurance and Long-term Effects of Adjuvant tamoxifen Treatment
2018)(
- Thesis › Doctoral thesis (compilation)
-
Mark
One-view digital breast tomosynthesis as a stand-alone modality for breast cancer detection : do we need more?
(
- Contribution to journal › Article
-
Mark
Intratumoural leukocyte infiltration is a prognostic indicator among pancreatic cancer patients with type 2 diabetes
(
- Contribution to journal › Article
-
Mark
A comprehensive analysis of polymorphic variants in steroid hormone and insulin-like growth factor-1 metabolism and risk of in situ breast cancer : Results from the Breast and Prostate Cancer Cohort Consortium
(
- Contribution to journal › Article
-
Mark
Abstract P1-06-01: Putting multigene signatures to the test: Prognostic assessment in population-based contemporary clinical breast cancer
(
- Contribution to journal › Published meeting abstract
-
Mark
Abstract P2-02-09: Breast cancer subtype distribution and circulating tumor DNA in response to neoadjuvant chemotherapy: Experiences from a preoperative cohort within SCAN-B
(
- Contribution to journal › Published meeting abstract
-
Mark
Abstract P2-03-01: Analytical validation of a standardized scoring protocol for Ki67 assessed on breast excision whole sections: An international multicenter collaboration
(
- Contribution to journal › Published meeting abstract
-
Mark
A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort
(
- Contribution to journal › Article
-
Mark
Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab : Results from the Phase II PROMIX trial
(
- Contribution to journal › Article